NeuroSense Therapeutics (NRSN) Non-Current Assets (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Non-Current Assets of $250000.0 for Q4 2025, up 95.31% sequentially from $128000.0 in Q2 2025, and up 44.51% YoY from $173000.0 in Q4 2024.
NeuroSense Therapeutics (NRSN) Non-Current Assets (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Non-Current Assets for 6 years, with the latest figure at $250000.0 in Q4 2025.
- Quarterly Non-Current Assets rose 44.51% year-over-year to $250000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $250000.0 (up 44.51% YoY) and the FY2025 annual result came in at $250000.0, up 44.51% from the prior year.
- Non-Current Assets rose to $250000.0 in Q4 2025 per NRSN's latest filing, from $128000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $307.0 million in Q2 2023 and troughed at $19000.0 in Q4 2021.
- A 5-year average of $20.7 million and a median of $269000.0 in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets soared 87865.62% in 2023, then sank 99.93% in 2024.
- Over 5 years, Non-Current Assets stood at $19000.0 in 2021, then surged by 1668.42% to $336000.0 in 2022, then declined by 19.94% to $269000.0 in 2023, then plunged by 35.69% to $173000.0 in 2024, then jumped by 44.51% to $250000.0 in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $250000.0, $128000.0, and $173000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 250,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 250,000.00 |
| Jun 30, 2025 | 128,000.00 |
| Dec 31, 2024 | 173,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 222,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Dec 31, 2023 | 269,000.00 |
| Sep 30, 2023 | 281,000.00 |
| Jun 30, 2023 | 307.00 Mn |
| Mar 31, 2023 | 317,000.00 |
| Dec 31, 2022 | 336,000.00 |
| Sep 30, 2022 | 338,000.00 |
| Jun 30, 2022 | 349,000.00 |
| Mar 31, 2022 | 329,000.00 |
| Dec 31, 2021 | 19,000.00 |
| Dec 31, 2020 | 13,000.00 |